









Markets
/
Stocks
/
nasdaq-lrmr
/

Larimar Therapeutics Inc

LRMR

4.280USD

-0.570-11.75%

Market hours （ET）Quotes delayed by 15 min

7.42MMarket Cap

LossP/E TTM



Larimar Therapeutics Inc

4.280

-0.570-11.75%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Larimar Therapeutics Inc

Currency: USD Updated: 2026-03-27

Key Insights

Larimar Therapeutics Inc's fundamentals are relatively weak, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 104 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 16.64.In the medium term, the stock price is expected to trend up.Despite a weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Larimar Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

104 / 391

Overall Ranking

219 / 4542

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Larimar Therapeutics Inc Highlights

StrengthsRisks

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide (CPP) technology platform. The Company’s lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin (FXN), an essential protein, to the mitochondria of patients with Friedreich's ataxia (FA). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Its CPP platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. The Company intends to use its proprietary platform to target additional orphan indications characterized by deficiencies in or alterations of intracellular content or activity.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Overvalued

The company’s latest PE is -2.03, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 86.20M shares, increasing 3.36% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 4.10K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 1.23.

Analyst Rating

Based on 11 analysts

Strong Buy

Current Rating

16.700

Target Price

+244.33%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-27

The current financial score of Larimar Therapeutics Inc is 5.45, ranking 364 out of 391 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

5.45

Change



Financials

2.04

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.42

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Larimar Therapeutics Inc's Company Valuation

Currency: USD Updated: 2026-03-27

The current valuation score of Larimar Therapeutics Inc is 6.05, ranking 336 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -2.03, which is -43.96% below the recent high of -1.14 and -675.67% above the recent low of -15.78.

Score

Industry at a Glance

Previous score

6.05

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 104/391

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-27

The current earnings forecast score of Larimar Therapeutics Inc is 9.27, ranking 9 out of 391 in the Biotechnology & Medical Research industry. The average price target is 18.00, with a high of 26.00 and a low of 7.00.

Score

Industry at a Glance

Previous score

9.27

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 11 analysts

Strong Buy

Current Rating

16.700

Target Price

+244.33%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

548

Total

Median

Average

Company name

Ratings

Analysts

Larimar Therapeutics Inc

LRMR

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

110

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-27

The current price momentum score of Larimar Therapeutics Inc is 6.89, ranking 118 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 5.68 and the support level at 3.88, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.13

Change

-0.24

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.138

Neutral

RSI(14)

51.304

Neutral

STOCH(KDJ)(9,3,3)

62.085

Buy

ATR(14)

0.371

Low Volatility

CCI(14)

-18.421

Neutral

Williams %R

76.667

Sell

TRIX(12,20)

0.362

Sell

StochRSI(14)

4.532

Sell

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

4.680

Sell

MA10

4.544

Sell

MA20

4.908

Sell

MA50

4.094

Buy

MA100

3.848

Buy

MA200

3.807

Buy

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Larimar Therapeutics Inc is 10.00, ranking 1 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 103.74%, representing a quarter-over-quarter increase of 19.27%. The largest institutional shareholder is The Vanguard, holding a total of 3.05M shares, representing 2.93% of shares outstanding, with 15.34% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Deerfield Management Company, L.P.

30.61M

Blue Owl Capital Holdings LP

5.85M

+18.77%

Millennium Management LLC

4.90M

+33.97%

BlackRock Institutional Trust Company, N.A.

2.97M

+7.93%

RTW Investments L.P.

3.13M

The Vanguard Group, Inc.

Star Investors

3.09M

+44.15%

Point72 Asset Management, L.P.

Star Investors

1.22M

AIGH Capital Management, LLC.

739.00K

Citadel Advisors LLC

1.48M

+10.57%

Geode Capital Management, L.L.C.

1.02M

+13.06%

Risk Assessment

Currency: USD Updated: 2026-03-27

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. No risk assessment score is currently available for Larimar Therapeutics Inc. The Biotechnology & Medical Research industry's average is 3.38. The company's beta value is 0.99. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.